Neurocrine Publishes Expert Guidelines for Glucocorticoid Reduction with CRENESSITY in CAH Patients

Event summary

  • Neurocrine Biosciences published peer-reviewed expert recommendations for glucocorticoid dose reduction in classic congenital adrenal hyperplasia (CAH) patients treated with CRENESSITY (crinecerfont).
  • The guidelines, published in The Journal of Clinical Endocrinology & Metabolism, provide structured algorithms for pediatric and adult patients.
  • CRENESSITY, approved in December 2024, is an adjunct treatment to control androgens in CAH patients aged four and older.
  • The recommendations aim to transition patients to more physiologic glucocorticoid dosing while maintaining cortisol replacement.

The big picture

Neurocrine's publication of expert-driven guidelines for CRENESSITY marks a strategic shift in CAH management, decoupling androgen control from supraphysiologic glucocorticoid use. This aligns with broader industry trends toward precision dosing and minimizing long-term steroid-related complications. The move positions Neurocrine to capture a larger share of the CAH treatment market, which has seen limited therapeutic innovation until recently.

What we're watching

Adoption Dynamics
How quickly clinicians adopt the new guidelines and integrate CRENESSITY into real-world CAH treatment protocols.
Clinical Outcomes
Whether the structured dose reduction algorithms improve long-term patient outcomes and reduce complications from supraphysiologic glucocorticoid exposure.
Market Positioning
The pace at which Neurocrine can differentiate CRENESSITY in the competitive landscape of CAH treatments.